Which weight loss injections work fastest, and what does that really mean?

Do tirzepatide and semaglutide produce results at different speeds?

Both medicines belong to the GLP-1 class of receptor agonists, which slow the rate at which food leaves the stomach and signal fullness to the brain. Tirzepatide goes a step further by also activating GIP receptors, making it the only dual-agonist weight-loss injection licensed in the UK. In the SURMOUNT-1 trial, adults taking tirzepatide lost an average of around 20–21% of body weight over 72 weeks at the highest dose, and in the direct head-to-head SURMOUNT-5 comparison, tirzepatide produced greater average loss than semaglutide 2.4mg. Semaglutide (Wegovy) produced approximately 15% average weight reduction over 68 weeks in the STEP 1 trial, a result that a higher 7.2mg dose approved in early 2026 appears to bring closer to tirzepatide territory. Neither is a rapid fix. Both start at low tolerability doses (the first pen of Mounjaro is 2.5mg, there to settle your system rather than drive weight loss) and titration typically takes several months before the maintenance dose is reached. That slower ramp is intentional: pushing too fast increases the chance of nausea, vomiting and other gastrointestinal side effects that can make treatment hard to sustain.

If you want to understand how quickly results tend to appear week by week, the short answer is that appetite usually shifts before the scales do.

What affects how fast a weight loss injection works for a given person?

Trials report averages across thousands of participants; your own trajectory will differ. Several factors influence how quickly someone responds. The dose matters most: people at higher maintenance doses consistently show greater and faster loss than those who plateau at lower doses because of side effects. Starting weight plays a role too, someone with a higher BMI often sees larger absolute changes early on, even if the percentage loss is similar. Diet and physical activity sit alongside the medicine, not beneath it. Both Mounjaro and Wegovy are licensed alongside a reduced-calorie diet and increased physical activity, because the medicine works by reducing appetite, not by replacing the energy deficit that comes from eating a little less and moving a little more. Gut sensitivity varies between people, which is exactly why doses begin low and increase gradually, some patients tolerate fast titration without issue, others need an extra month at each step. None of this can be predicted in advance, which is why understanding what weight loss injections actually do before you start is more useful than focusing on the fastest possible result.

One practical note our prescribers hear regularly: keeping your pen in the fridge door (between the milk and the condiments) makes the weekly routine easier to remember, and a cool pen is less likely to cause injection-site discomfort than one that has warmed unevenly.

Are there any injectable weight loss products that claim to work faster than GLP-1 medicines?

You may come across claims for amino acid injections, lipotropic blends, or other injectable products marketed as rapid fat-burners. These fall outside the licensed medicines framework for weight management in the UK. Amino acid injections marketed for weight loss are not supported by the same body of regulatory evidence as GLP-1 medicines and are not prescribed through GPhC-registered pharmacies for this purpose. The MHRA has also warned publicly about counterfeit weight-loss pens sold online without a prescription, some have contained substances never intended for injection, leading to hospitalisations. The only weight loss injections with a UK licence, robust clinical-trial evidence, and a clear safety record are tirzepatide and semaglutide. Faster-sounding alternatives that bypass clinical oversight are not a shortcut; they carry real risk. If you want to understand how pricing of weight loss injections works and what legitimate treatment actually costs, that context is worth reading before making any decision.

Who can access these injections, and what does clinical assessment involve?

The licensed eligibility criteria for private treatment are set by each medicine's prescribing information: adults with a BMI of 30 or above, or 27 and above with at least one weight-related health condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, or type 2 diabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. A BMI figure alone never guarantees approval; the prescriber looks at your full health history, any medicines you already take, and whether treatment is safe and appropriate for you. At nume, that review is carried out personally by a GPhC-registered Independent Prescriber, a named clinician reads your consultation, not a piece of software. The consultation is free, and if treatment is clinically suitable the prescription and next-working-day delivery are included in one transparent price. If you want a broader overview of what these medicines are before starting a consultation, the weight loss injections guide covers the essentials, and the NHS provides patient-level information on tirzepatide through the NHS medicines pages. Side effects, storage, and what to do if a dose is missed are all covered in the Patient Information Leaflet supplied with your treatment, and NICE's appraisal of tirzepatide (TA1026) sets out the clinical evidence base in full.